Side-by-side · Research reference

CardiogenvsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BPhase 1HUMAN-REVIEWED10/36 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Cardiogen

GHRP-6

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

GHRP-6

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

100–200 mcg per injectionBowers 1990

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

1–3× per day

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Phase 1 + clinical practiceBowers 1990

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

8–12 weeks on / 4 off

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-meal preferred for appetite support

Half-life

—

~15 minMalagón 1999

04Side Effects & Safety

Parameter

Cardiogen

GHRP-6

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Injection site reaction

—

Mild

Cancer risk

—

Contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

Cardiogen

GHRP-6

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

SQ — abdomen. Rotate sites.

3. Timing

Variable — often evening injection. No established circadian preference.

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

GHRP-6

— no documented stacks